Advanced Life Sciences Holdings Inc. (ADLS) Financ
Post# of 250675
Posted On: 11/17/2014 1:36:25 AM
Advanced Life Sciences Holdings Inc. (ADLS) Financials Nov 13, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Advanced Life Sciences Holdings Inc.
Fiscal year is January-December. All values USD millions. 2006 2007 2008 2009 2010 5-year trend
Sales/Revenue 39,788 0 240,830 2.79M 752,853
Cost of Goods Sold (COGS) incl. D&A 131,114 206,755 218,796 106,907 32,513
COGS excluding D&A 0 0 0 0 0
Depreciation & Amortization Expense 131,114 206,755 218,796 106,907 32,513
Depreciation - 206,755 218,796 - -
Amortization of Intangibles - - - - -
Gross Income (91,326) (206,755) 22,034 2.69M 720,340
2006 2007 2008 2009 2010 5-year trend
SG&A Expense 22.53M 32.37M 22.61M 10.68M 6.84M
Research & Development 17.2M 25.74M 15.71M 4.46M 2.5M
Other SG&A 5.33M 6.63M 6.9M 6.22M 4.34M
Other Operating Expense 0 0 0 0 0
Unusual Expense 0 0 0 0 2.51M
EBIT after Unusual Expense 0 0 0 0 (2.51M)
Non Operating Income/Expense 939,052 0 0 (146,092) 244,479
Non-Operating Interest Income 1.65M 717,884 306,846 11,561 8,360
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 511,884 466,963 525,703 1.04M 946,191
Gross Interest Expense 511,884 466,963 525,703 1.04M 946,191
Interest Capitalized - - - - 0
Pretax Income (20.54M) (32.32M) (22.8M) (9.16M) (9.32M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 0 0
Income Tax - Current Foreign 0 0 0 0 0
Income Tax - Deferred Domestic 0 0 0 0 0
Income Tax - Deferred Foreign 0 0 0 0 0
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (20.54M) (32.32M) (22.8M) (9.16M) (9.32M)
Minority Interest Expense 0 0 0 0 0
Net Income (20.54M) (32.32M) (22.8M) (9.16M) (9.32M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (20.54M) (32.32M) (22.8M) (9.16M) (9.32M)
Preferred Dividends 175,000 175,000 175,000 175,000 175,000
Net Income Available to Common (20.72M) (32.5M) (22.98M) (9.34M) (9.5M)
EPS (Basic) (23.40) (33.60) (17.70) (4.80) (1.80)
Basic Shares Outstanding 884,892 963,667 1.3M 1.93M 5.11M
EPS (Diluted) (23.40) (33.60) (17.70) (4.80) (1.80)
Diluted Shares Outstanding 884,892 963,667 1.3M 1.93M 5.11M
EBITDA (22.49M) (32.37M) (22.37M) (7.89M) (6.09M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Advanced Life Sciences Holdings Inc.
Fiscal year is January-December. All values USD millions. 2006 2007 2008 2009 2010 5-year trend
Sales/Revenue 39,788 0 240,830 2.79M 752,853
Cost of Goods Sold (COGS) incl. D&A 131,114 206,755 218,796 106,907 32,513
COGS excluding D&A 0 0 0 0 0
Depreciation & Amortization Expense 131,114 206,755 218,796 106,907 32,513
Depreciation - 206,755 218,796 - -
Amortization of Intangibles - - - - -
Gross Income (91,326) (206,755) 22,034 2.69M 720,340
2006 2007 2008 2009 2010 5-year trend
SG&A Expense 22.53M 32.37M 22.61M 10.68M 6.84M
Research & Development 17.2M 25.74M 15.71M 4.46M 2.5M
Other SG&A 5.33M 6.63M 6.9M 6.22M 4.34M
Other Operating Expense 0 0 0 0 0
Unusual Expense 0 0 0 0 2.51M
EBIT after Unusual Expense 0 0 0 0 (2.51M)
Non Operating Income/Expense 939,052 0 0 (146,092) 244,479
Non-Operating Interest Income 1.65M 717,884 306,846 11,561 8,360
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 511,884 466,963 525,703 1.04M 946,191
Gross Interest Expense 511,884 466,963 525,703 1.04M 946,191
Interest Capitalized - - - - 0
Pretax Income (20.54M) (32.32M) (22.8M) (9.16M) (9.32M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 0 0
Income Tax - Current Foreign 0 0 0 0 0
Income Tax - Deferred Domestic 0 0 0 0 0
Income Tax - Deferred Foreign 0 0 0 0 0
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (20.54M) (32.32M) (22.8M) (9.16M) (9.32M)
Minority Interest Expense 0 0 0 0 0
Net Income (20.54M) (32.32M) (22.8M) (9.16M) (9.32M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (20.54M) (32.32M) (22.8M) (9.16M) (9.32M)
Preferred Dividends 175,000 175,000 175,000 175,000 175,000
Net Income Available to Common (20.72M) (32.5M) (22.98M) (9.34M) (9.5M)
EPS (Basic) (23.40) (33.60) (17.70) (4.80) (1.80)
Basic Shares Outstanding 884,892 963,667 1.3M 1.93M 5.11M
EPS (Diluted) (23.40) (33.60) (17.70) (4.80) (1.80)
Diluted Shares Outstanding 884,892 963,667 1.3M 1.93M 5.11M
EBITDA (22.49M) (32.37M) (22.37M) (7.89M) (6.09M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
(0)
(0)